Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Durata Therapeutics International, the Dutch subsidiary of US-based Durata Therapeutics, has entered into a license and supply agreement with Angelini, an international group leader in the pharmaceutical and mass-market sectors, to commercialize dalbavancin in 36 countries.
Subscribe to our email newsletter
Dalbavancin will be commercialized in Italy, Spain, Poland, Portugal, many Eastern European countries, Russia, Turkey and Commonwealth of Independent States.
As part of the deal, Durata will receive an upfront payment from Angelini of $15m and another $10m upon European Medicines Agency (EMA) approval.
Durata will also receive payments upon the achievement of certain countries’ pricing approvals and sales milestones, as well as royalties on sales.
The company’s marketing authorization application (MAA) for dalbavancin is under review with the EMA and expects a decision in the first half of 2015.
Worldwide rights for development and commercialization or partnering of dalbavancin are owned by Durata.
Currently, Durata is commercializing Dalvance (dalbavancin) for injection in the US and, if approved in the EU, may choose to directly commercialize in the remaining parts of Western Europe, including the UK, Germany, and France.
Durata chief executive officer Paul Edick said the company is happy to have entered into this agreement with Angelini, a well-respected pharmaceutical company with rich history and significant experience marketing hospital-based products.
"This partnership is aligned with our strategy to bring dalbavancin to the market for the millions of people who may benefit from an innovative treatment option for serious skin infections in today’s evolving health care environment," Edick said.
Angelini Pharmaceutical Division chief executive officer Gianluigi Frozzi said the company is proud of partnering dalbavancin with Durata for treating patients affected by serious skin infections.
"The new approach will allow patients, healthcare professionals and hospitals to overcome the standard daily or twice-daily IV antibiotic infusions," Frozzi said.
"The agreement is part of the Angelini effort in the field of treatment of infectious diseases. Once approved in the EU, our experienced sales force and extensive network will bring dalbavancin to over 30 countries."